CGEM
Cullinan Therapeutics, Inc.
Biotechnology · Healthcare · United States
15.03
close · 2026-10-30
value
65
cheaper than peers65
quality
79
stronger fundamentals79
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | 15.8% | 100 |
| earnings yield, 2 years ago | -21.4% | 62 |
| earnings yield, 1 year ago | -18.5% | 59 |
| earnings yield, latest year | -22.4% | 54 |
| cash flow yield, 3 years ago | -13.8% | 50 |
| cash flow yield, 1 year ago | -15.7% | 50 |
| cash flow yield, 2 years ago | -14.6% | 49 |
| cash flow yield, latest year | -19.0% | 47 |
| price to book | 3.01× | 45 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.7% | 78 |
| return on equity | -48.2% | 67 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $924M |
| free cash flow | -$102.8M |
| employees | 109 |
| first trade | 2021-01-08 |
| next earnings | 2026-11-14 |
| fundamentals updated | 2026-08-06 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -3.36 | -2.78 | -3.21 | 2.38 | not reported |
| free cash flow | -$175.8M | -$145.3M | -$134.5M | -$127.8M | not reported |
| net income | -$219.9M | -$167.4M | -$153.2M | $111.2M | not reported |
| revenue | $0 | $0 | $0 | $0 | not reported |
| unusual items | not reported | $0 | -$440,000 | $276.8M | $0 |